Crispr Therapeutics AG (NASDAQ:CRSP) saw unusually large options trading activity on Tuesday. Stock investors bought 2,189 put options on the company. This is an increase of 1,321% compared to the average volume of 154 put options.

In other Crispr Therapeutics news, President Rodger Novak sold 50,000 shares of Crispr Therapeutics stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $45.00, for a total transaction of $2,250,000.00. Following the completion of the sale, the president now directly owns 898,007 shares in the company, valued at $40,410,315. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Lawrence Otto Klein sold 20,000 shares of Crispr Therapeutics stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $50.02, for a total transaction of $1,000,400.00. Following the completion of the transaction, the insider now owns 31,579 shares of the company’s stock, valued at approximately $1,579,581.58. The disclosure for this sale can be found here. Insiders have sold 140,000 shares of company stock worth $6,670,400 over the last ninety days. 21.40% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the business. Cookson Peirce & Co. Inc. acquired a new position in Crispr Therapeutics during the second quarter worth about $382,000. Aperio Group LLC acquired a new position in Crispr Therapeutics during the second quarter worth about $153,000. ARK Investment Management LLC grew its holdings in Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after acquiring an additional 701,332 shares during the period. BNP Paribas Arbitrage SA acquired a new position in Crispr Therapeutics during the second quarter worth about $41,000. Finally, Nikko Asset Management Americas Inc. grew its holdings in Crispr Therapeutics by 324.3% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares during the period. Institutional investors own 48.92% of the company’s stock.

CRSP has been the subject of a number of research reports. Needham & Company LLC lifted their price objective on shares of Paycom Software from $28.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday. Evercore ISI began coverage on shares of Homology Medicines in a research report on Thursday, April 11th. They set an “outperform” rating and a $29.00 price objective for the company. Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. BTIG Research upped their price target on shares of Crispr Therapeutics from $51.00 to $59.00 and gave the company a “positive” rating in a research report on Tuesday. Finally, Chardan Capital set a $73.00 price target on shares of Crispr Therapeutics and gave the company a “buy” rating in a research report on Friday, June 7th. Two analysts have rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $57.40.

Crispr Therapeutics stock traded down $0.18 during trading hours on Wednesday, reaching $50.54. 87,680 shares of the stock were exchanged, compared to its average volume of 451,063. The stock has a market capitalization of $2.68 billion, a PE ratio of -14.69 and a beta of 3.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 15.84 and a current ratio of 15.84. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $59.00. The company’s 50 day moving average price is $47.46.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, July 29th. The company reported ($1.01) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.84). The firm had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $47.57 million. Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The firm’s quarterly revenue was down 70.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.82) EPS. Equities research analysts anticipate that Crispr Therapeutics will post -3.7 earnings per share for the current fiscal year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.